ONCAlert | 2018 Gastrointestinal Cancers Symposium

Gastric Cancer MORE >>

According to findings presented at the 2018 Gastrointestinal Cancers Symposium, the combination of the VEGFR-2 inhibitor ramucirumab (Cyramza) plus the anti–PD-L1 agent durvalumab (Imfinzi) demonstrated antitumor activity in a phase Ia/b study of patients with previously treated advanced gastric or gastroesophageal junction adenocarcinoma.

Latest JournalAll Journals >>

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.